OpenNashEarnings

Medical Devices · NYSE: EW

Edwards Lifesciences earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 9 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Edwards raised its 2026 outlook after TAVR share gains and a new CMS coverage decision, while TMTT growth from PASCAL and EVOQUE added a second structural heart engine.

Edwards' TAVR business grew on a heightened clinical focus on treating aortic stenosis earlier, with modest share gains and stable pricing. CMS finalized an updated TAVR coverage policy, and Japan granted dedicated reimbursement for SAPIEN 3 Ultra RESILIA. In mitral and tricuspid, mitral and tricuspid procedure volumes grew in double digits, and the FDA approved PASCAL Ace with Capture Clarity and PASCAL Precision for tricuspid.

Read the Q3 2026 summary →Official transcript (PDF) ↗

Quarters

KPI history

Revenue$1.7B+10.5% y/yQ3 2026
Q4 2024: $1.4BQ4 ’24$1.4BQ1 2025: $1.4BQ1 ’25$1.4BQ2 2025: $1.5BQ2 ’25$1.5BQ3 2025: $1.6BQ3 ’25$1.6BQ4 2025: $1.6B (worked out from the annual figure)Q4 ’25$1.6BQ1 2026: $1.6BQ1 ’26$1.6BQ2 2026: $1.7BQ2 ’26$1.7BQ3 2026: $1.7BQ3 ’26$1.7B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$1.4B
Q1 2025$1.4B
Q2 2025$1.5B
Q3 2025$1.6B
Q4 2025$1.6B *
Q1 2026$1.6B
Q2 2026$1.7B
Q3 2026$1.7B
Diluted EPS (GAAP)$0.53+6.0% y/yQ3 2026
Q4 2024: $0.65Q4 ’24$0.65Q1 2025: $0.61Q1 ’25$0.61Q2 2025: $0.56Q2 ’25$0.56Q3 2025: $0.50Q3 ’25$0.50Q1 2026: $0.66Q1 ’26$0.66Q2 2026: $0.42Q2 ’26$0.42Q3 2026: $0.53Q3 ’26$0.53
Data
Q4 2024$0.65
Q1 2025$0.61
Q2 2025$0.56
Q3 2025$0.50
Q1 2026$0.66
Q2 2026$0.42
Q3 2026$0.53

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin17.4%−2.4 pts y/yQ3 2026
Q4 2024: 22.6%Q4 ’2422.6%Q1 2025: 27.9%Q1 ’2527.9%Q2 2025: 26.8%Q2 ’2526.8%Q3 2025: 19.8%Q3 ’2519.8%Q4 2025: 9.6%Q4 ’259.6%Q1 2026: 29.0%Q1 ’2629.0%Q2 2026: 29.5%Q2 ’2629.5%Q3 2026: 17.4%Q3 ’2617.4%
Data
Q4 202422.6%
Q1 202527.9%
Q2 202526.8%
Q3 202519.8%
Q4 20259.6%
Q1 202629.0%
Q2 202629.5%
Q3 202617.4%
Free cash flow$506.7M−1.8% y/yQ3 2026
Q4 2024: -$177.3MQ4 ’24-$177.3MQ1 2025: $224.4MQ1 ’25$224.4MQ2 2025: $240.9MQ2 ’25$240.9MQ3 2025: $516.2MQ3 ’25$516.2MQ4 2025: $353.5MQ4 ’25$353.5MQ1 2026: -$21.1MQ1 ’26-$21.1MQ2 2026: $585.0MQ2 ’26$585.0MQ3 2026: $506.7MQ3 ’26$506.7M
Data
Q4 2024-$177.3M
Q1 2025$224.4M
Q2 2025$240.9M
Q3 2025$516.2M
Q4 2025$353.5M
Q1 2026-$21.1M
Q2 2026$585.0M
Q3 2026$506.7M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$1.4B$1.4B$1.5B$1.6B$1.6Bd$1.6B$1.7B$1.7B
Gross margin78.9%78.7%77.5%77.8%78.1%78.0%77.5%78.5%
Operating income$312.6Md$394.8M$411.2M$307.1M$151.1Md$477.6M$513.2M$299.1M
Operating margin22.6%27.9%26.8%19.8%9.6%29.0%29.5%17.4%
Net income$385.6M$358.0M$333.2M$291.1M$91.2Md$380.7M$241.9M$307.5M
Diluted EPS$0.65$0.61$0.56$0.50—$0.66$0.42$0.53
Operating cash flow-$127.5Md$280.4M$290.2Md$573.7Md$450.9Md$43.8M$651.9Md$570.3Md
Capital expenditure$49.8Md$56.0M$49.3Md$57.5Md$97.4Md$64.9M$66.9Md$63.6Md
Free cash flow-$177.3M$224.4M$240.9M$516.2M$353.5M-$21.1M$585.0M$506.7M
R&D expense$271.1Md$254.6M$276.2M$280.7M$267.7Md$263.3M$278.9M$281.4M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings